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(RAD. T.), n.M.R.E., F.F.R. (R.C.S.L), Departmelll of Radiotherapy, Pretoria General Hospital and University of
Pretoria
Since early in 1962 Chromomycin A 3 (Toyomycin) has
been used in clinical trials for patients with advanced
cancer at the Pretoria General Hospital. The results of
our first experience with this anti·tumour antibiotic were
reported in 1964.' The present report deals with the results
obtained in 123 patients treated with this agent.
Chromomycin A 3 is the most effective tumour-suppres-
sing part of chromomycin, an antibiotic discovered in a
culture of Streplomyces griseus Nc. 7 by the Takeda Re-
search Laboratory in Japan.,·3 Chromomycin A 3, Mithra-
mycin and Olivomycin are three chemically related anti-
biotics. The latter two were discovered in the United
States of America' and the Soviet Union' respectively.
These substances are inactive against Gram·negative
organisms, but inhibit the growth of Gram-positive
organisms.
Chromomycin A 3 inhibits RNA synthesis by the RNA
polymerase, but only when the DNA template contains
guanine 6 Goldberg,' of Harvard Medical School and Beth
Israel Hospital, Boston, has done extensive studies on
this and other actions of chromomycin, including those
that show that Chromomycin A 3, Mithrarnycin and
Olivomycin prcduce different spectra with DNA but only
in the presence of a divalent cation. The magnitude of the
change in the spectrum of chromomycin produced by
DNA is a function of the Mg++ concentration.
MATERIALS AND METHODS
All patients had histologically confirmed inoperable malig-
nant neoplasms. The patients treated by intravenous
Chromomycin A 3 were as follows: Ovarian cancer 15,
cancer of the cervix 7, cancer of the corpus 2, cancer of
the stomach 10, cancer of the colon and rectum 11, cancer
of the pancreas 3, ca ncer of the bronchus 21, cancer of
the bladder 4, hypernephroma 3, seminoma 2, cancer of
the prostate 2. malignant hepatoma 8, cancer of the
pharynx 3, cancer of unknown origin 5, cancer of the
penis I, Hodgkin's disease 5, reticulum-cell sarcoma 4,
glioblastoma multifonne 4, and 1 each of the following:
mixed tumour of the broad ligament, fibrosarcoma, syno-
viosarcoma. spindle-cell sarcoma, neuroblastoma, Schwan-
noma. and lymphosarcoma.
Thirty-five p~tients received concomitant radiotherapy.
In these patients the Chromornycin A 3 was usually given
only on the days that radiotherapy was administered.
Twenty of these patients had bronchogenic cancer.
A further 5 pa;ients with squamous carcinoma of the
head and neck were treated by continuous intra·arterial
Chromomycin A 3. The intra-arterial chromornycin was
administered by means of a pump connected to an intra-
arterial catheter which was placed in the arterial supply
to the tumour area under general anaesthesia. Visualiza-
tion of the tumour blood supply was achieved by first
*J.n receipt of a grant from the "Tational Cancer Association of South
Africa.
injecting suIphan blue into the catheterized artery and by




Except for pain followed by induration if the drug was
accidentally injected extravascularly, no side-effects were
encountered. Although in some patients a mild leucopenia
occurred, in several patients a rise in white blood cell
count followed Chromomycin A 3 administration.
We have previously described skin changes ascribed to
Chromomycin A 3, but these are seldom of clinical im-
portance, although regularly discernible histologically
when large total doses are employed.'
Therapeutic Rcsponse
The results of treatment are shown III Table I; 123
patients were treated:
49 showed neither subjective nor objective improvement (0 - 0
in Table).
18 showed sul?jective response only (0 - A in Table).
5 showed objective response without subjective benefit (0 - B
in Table).
15 showed subjective and objective response of less than I
month's duration (0 - C in Table).
36 showed distinctive subjective benefit with favourable ob-
jective changes in all measurable criteria for 1 month or
more (1 - A in Table).
Of the 35 patients who received concomitant radio-
therapy:
13 showed neither subjective nor objective improvement (0 - 0
in Table).
2 showed subjective response only (0 - A in Table).
o showed objective response without subjective benefit (0 - B
in Table).
4 showed subjective and objective improvement of less than
1 month's duration (0 - C in Table).
16 showed distinctive subjective benefit with favourable ob-
jective changes in all measurable criteria for 1 month or
more (I - A in Table).
SUMMARY AND CONCLUSIONS
This drug was used in patients with advanced cancer,
most of whom were already resistant to standard cyto-
static drugs and many of whom had previously received
radiotherapy. The drug was well tolerated by even mori-
bund patients. In this group of 123 patients some response
was observed in 76 patients, although significant objective
response of more than 1 month's duration was only seen
in 36 patients. Of the 36 patients who showed worth·while
improvement, 16 received concomitant radiotherapy, and
9 of these had bronchus cancer and received radical doses
of telecobalt. The most encouraging results with Chromo-
mycin A 3 on its own have been in the treatment of
stomach, colon and gynaecological malignancies.
It is concluded that the agent is worth while when
other treatment cannot be administered because of leuco-
penia or the poor general condition of the patient, but
-------- -- -- - ------------------~~~~==="""""====-=====~~
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...\bbreviations used: erA3 = Chromomyc:in A 3.
R T = Radiotherapy.
Symbols used for response are those suggested by Karnofsky.lI
that under these circumstances the drug is well worth
on idering.
This drug can be administered concomitantly with radi-
cal radiotherapy without adding to total patient toxicity
and it further value may lie in this field.
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UNILATERAL SPONDYLOLYSIS
A T OBSERVATION MADE ON POSTERO-ANTERIOR RADIOGRAPHS TAKE TIT THE ERECT POSITIO
A. WOLPOWITZ, 1.B., CH.B., D.M.R., M.D., Cape Town
Some years :lgo I observed a marked narrowing of the
space between the transverse process of L.S and the
uperior margin of the ilium, and quite frequently even
overlap of the aforesaid transverse process and the ilium
and a widening of the space between the transverse proces-
ses of LA and L.5, on the side of a unilateral gap in the
